Recent SILO News
- Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury • GlobeNewswire Inc. • 05/07/2026 12:05:00 PM
- Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD • GlobeNewswire Inc. • 04/29/2026 01:08:00 PM
- Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents • GlobeNewswire Inc. • 04/22/2026 08:15:00 PM
- Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics • GlobeNewswire Inc. • 04/20/2026 10:34:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/16/2026 08:15:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/16/2026 04:15:03 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/14/2026 09:10:38 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/14/2026 08:38:21 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/10/2026 09:29:48 PM
- Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy • GlobeNewswire Inc. • 04/06/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:40:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 10:00:43 PM
- Silo Pharma Announces Share Buyback Program • GlobeNewswire Inc. • 02/23/2026 09:15:00 PM
- Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio • GlobeNewswire Inc. • 02/18/2026 01:28:00 PM
- Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 • GlobeNewswire Inc. • 12/30/2025 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2025 02:04:03 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/26/2025 09:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 11:35:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 09:00:32 PM
- Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD • GlobeNewswire Inc. • 11/17/2025 01:05:00 PM
